GlassScriptPhysician profile
Shareda Mickelle Young
NPI 1407447352
$4,082.03
in general payments reported to CMS, 2019-2025
34 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 85% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $693 · 2022: $822 · 2023: $900 · 2024: $605 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,567.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $594.48 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $546.98 | 2021-2024 | |
| Novo Nordisk INC | $397.03 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $320.59 | 2021-2024 | |
| Amgen INC. | $283.89 | 2023-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.15 | 2021-2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $210.03 | 2025 | Onpattro |
| Novartis Pharmaceuticals Corporation | $166.12 | 2021-2025 | |
| Pfizer INC. | $160.81 | 2021-2025 | |
| Cvrx, INC. | $157.52 | 2025 | Barostim Neo System |
| Dexcom, INC. | $130.84 | 2021-2023 | Dexcom G6 Transmitter |
| Atricure, INC. | $129.94 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Glaxosmithkline, LLC. | $128.69 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Abiomed | $72.97 | 2025 | |
| Amarin Pharma, INC. | $59.07 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $54.32 | 2021-2024 | Mounjaro |
| Medtronic, INC. | $47.67 | 2022-2023 | Minimed 770g, Minimed 780g |
| Esperion Therapeutics, INC. | $37.15 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.88 | 2025 | Lifevest |
| Eisai INC. | $29.28 | 2021 | |
| Recor Medical INC | $25.38 | 2024 | Paradise Renal Denervation System |
| Philips North America LLC | $25.18 | 2024 | (Cm9) Amb Mon & Diag Und |
| Acadia Pharmaceuticals INC | $24.91 | 2023 | Nuplazid |
| Xeris Pharmaceuticals, INC. | $24.62 | 2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $22.41 | 2021 | |
| Paratek Pharmaceuticals, INC. | $21.71 | 2023 | Nuzyra |
| Kiniksa Pharmaceuticals International, Plc | $19.43 | 2024 | Arcalyst |
| Biohaven Pharmaceutical Holding Company LTD. | $18.79 | 2022 | |
| Irhythm Technologies, INC. | $17.35 | 2024 | Zio Xt Patch, Zio Monitor |
| Merck Sharp & Dohme LLC | $17.14 | 2022 | |
| Astellas Pharma US INC | $14.85 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.85 | 2021 | |
| Sanofi Pasteur INC. | $13.77 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shareda Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.